Thalassemias: Overview of Pathophysiology and Treatment

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

K. Fertrin

Impact and Risks of Chronic Anemia in Thalassemia Patients

Farrukh Shah

Thalassemia: Overview of Pathophysiology and Risk for Malignancies

Ali Taher

Case-Based Discussion: Managing Non-Transfusion-Dependent Thalassemia

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

A. Taher

Managing Benign Hematology Disorders

Indy Hematology Review

C. Kessler

Mitapivat for Thalassemia: Results From the Ph3 ENERGIZE-T Study

Stefan Eber

Optimal Life-Long Management and Curative Therapies for Transfusion-…

Robert Klaassen

Importance of Continuous Monitoring in Thalassemia Patients

Raffaella Origa

Principles of Iron Management in Thalassemia

Nita Radhakrishnan

Beyond Transfusion: Current Treatment Options for Managing Thalassem…

Abdulrahman Nasiri

Highlights in Red Cell and Platelet Disorders From ASH 2023

Insights from 2023 ASH Annual Meeting

M. Blinder

Molecular Basis of Thalassemia

Norafiza Mohd Yasin

Principles of Transfusion Therapy for Thalassemia

Nita Radhakrishnan

Treatment of Thalassemia From Transplant to Novel Agents

Nita Radhakrishnan

Updates in Cellular Therapy for Sickle Cell Disease and Beta-Thalass…

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

S. Peslak

Importance of PK Activation in Thalassemias

Ilham Youssry

Overview of the Pathogenesis of Thalassemia

Nita Radhakrishnan

Mitapivat in Adults With Alpha- or Beta-Non-Transfusion-Dependent Th…

Ali Taher

State-of-the-Art in Managing Thalassemias

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

M. Cappellini

ASH 2023 Insights: "Pyruvate Kinase Activators - Targeting Red Cell …

Insights from 2023 ASH Annual Meeting

K. Kuo